Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10962731 | Vaccine | 2016 | 5 Pages |
Abstract
With the availability of the nonavalent human papillomavirus (HPV) vaccine, vaccinees, parents and healthcare providers need guidance on how to complete an immunization course started with the bi- or quadrivalent vaccine and whether to revaccinate individuals who have completed a full immunization course with the bi- or quadrivalent vaccine. To answer these questions three parameters should be considered: age at the start of vaccination (9 to 14 years of age versus 15 years and older, the cut-off for 2 or 3 doses schedule), the number of doses already received and the time interval between doses. Based on a number of scenarios, we propose that the 9-valent vaccine can be used to complete an incomplete vaccination regimen or might be added to a previous completed schedule to extend protection.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Pierre Van Damme, Paolo Bonanni, F. Xavier Bosch, Elmar Joura, Susanne Krüger Kjaer, Chris J.L.M. Meijer, Karl-Ulrich Petry, Benoit Soubeyrand, Thomas Verstraeten, Margaret Stanley,